Kapiva secures over USD 60 million in Series D funding led by 360 ONE Asset and Vertex Growth to enhance its Ayurvedic product offerings and health-tech capabilities.

Information on the Target

Kapiva, a leading innovator in modern Ayurvedic healthcare, has successfully secured over USD 60 million (approximately INR 510 crores) in its Series D funding round, which includes USD 28 million (INR 240 crores) in primary investments. The remaining funds were utilized to provide an exit for earlier investors. This funding round was spearheaded by 360 ONE Asset and Vertex Growth, with contributions from existing investors including Vertex Ventures Southeast Asia and India, along with 3one4 Capital.

The newly acquired capital will be directed towards enhancing Kapiva's research and development, boosting manufacturing capabilities, investing in large-scale brand building, and establishing a comprehensive health-tech ecosystem. Over the past three years, Kapiva has experienced remarkable growth, achieving over 80% year-on-year expansion and reaching an annual revenue run rate (ARR) exceeding INR 550 crores. The company has developed a robust distribution network that encompasses general trade, modern trade, pharmacy, digital commerce platforms, and its own website, while employing over 500 people.

Industry Overview in India

India's wellness industry is undergoing a significant transformation, driven by a rising awareness of health and preventive care among consumers. The traditional practices of Ayurveda are gaining traction globally as more con